This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


ALK-Abello A/S

Drug Names(s): epinephrine auto-injector

Description: Epinephrine (adrenaline) is a direct-acting sympathomimetic drug that acts as an agonist at alpha and beta-adrenergic receptors. It produces vasoconstriction to counteract the vasodilation and resulting hypotension associated with anaphylaxis. The bronchodilatory effects of epinephrine and its ability to reduce mucosal edema relieve bronchoconstriction and improve respiratory effort.

Deal Structure: ALK-Abello and CSL
In February 2015, ALK and bioCSL announced that they have entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALKs sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as GRAZAX in Europe and GRASTEK in North America), and its adrenaline auto-injector, Jext. ALK will be responsible for product supply and bioCSL will undertake registration and commercialisation of the products.

As part of the agreement, ALK will receive a minor upfront payment of an undisclosed amount, followed by a milestone payment upon approval of the HDM SLIT-tablet in Australia. ALK will sell products to bioCSL at a pre-agreed price structure ensuring a certain split of the final in-market revenues generated by bioCSL.

Partners: CSL Limited

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug